ISR Immune System Regulation Holding AB (publ)

DB:5JK Stock Report

Market Cap: €8.7m

ISR Immune System Regulation Holding Past Earnings Performance

Past criteria checks 0/6

ISR Immune System Regulation Holding's earnings have been declining at an average annual rate of -49.6%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 69.5% per year.

Key information

-49.6%

Earnings growth rate

-14.5%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate69.5%
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How ISR Immune System Regulation Holding makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:5JK Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 220-25729226
31 Mar 220-16826141
31 Dec 210-792256
30 Sep 210-602040
30 Jun 210-411824
31 Mar 210-361620
31 Dec 200-311416
30 Sep 200-291315
30 Jun 200-281214
31 Mar 200-281315
31 Dec 190-291316
30 Sep 190-291415
30 Jun 190-281414
31 Mar 190-251212
31 Dec 180-211110
30 Sep 180-201319
30 Jun 180-181117
31 Mar 180-181014
31 Dec 170-21912
30 Sep 170-3010
30 Jun 170-2140
31 Mar 170-2720
31 Dec 160-1450

Quality Earnings: 5JK is currently unprofitable.

Growing Profit Margin: 5JK is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 5JK is unprofitable, and losses have increased over the past 5 years at a rate of 49.6% per year.

Accelerating Growth: Unable to compare 5JK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5JK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).

Return on Equity

High ROE: 5JK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/05 10:58
End of Day Share Price 2022/12/07 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ISR Immune System Regulation Holding AB (publ) is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ethel Szpilman LuvallRedeye